scholarly journals Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual & volumetric analysis

2017 ◽  
pp. 20170163
Author(s):  
Augustin Lecler ◽  
Ariane Dunant ◽  
Suzette Delaloge ◽  
Delphine Wehrer ◽  
Tania Moussa ◽  
...  
Keyword(s):  
Mutation Carrier ◽  
Breast Tissue ◽  
Brca Mutation ◽  
Volumetric Analysis ◽  
Density Change ◽  
Brca Mutation Carrier ◽  
Tissue Density ◽  
Breast Tissue Density

scholarly journals The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are BRCA Mutation Carrier

2017 ◽  
Vol 20 (3) ◽  
pp. 279 ◽  
Author(s):  
Ju-Yeon Kim ◽  
Hyeong-Gon Moon ◽  
Young-Joon Kang ◽  
Wonshik Han ◽  
Woo-Chul Noh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mutation Carrier ◽  
Brca Mutation ◽  
Reproductive Factors ◽  
Brca Mutation Carrier

Outcomes after Surgery for Early Stage Breast Cancer in Women Staged With Preoperative Breast Magnetic Resonance Imaging According to Breast Tissue Density

2019 ◽  
Vol 1 (2) ◽  
pp. 115-121
Author(s):  
Renata Faermann ◽  
Jonathan Weidenfeld ◽  
Leonid Chepelev ◽  
Wayne Kendal ◽  
Raman Verma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Tissue ◽  
Early Stage ◽  
Disease Free Survival ◽  
Breast Mri ◽  
Early Stage Breast Cancer ◽  
Free Survival ◽  
Tissue Density ◽  
Breast Tissue Density ◽  
Preoperative Breast Mri

Abstract Purpose To determine surgical outcomes and breast cancer disease-free survival outcomes of women with early stage breast cancer with and without use of preoperative breast MRI according to breast tissue density. Methods Women with early stage breast cancer diagnosed from 2004 to 2009 were classified into 2 groups: 1) those with dense and heterogeneously dense breasts (DB); 2) those with nondense breasts (NDB) (scattered fibroglandular and fatty replaced tissue). The 2 groups were reviewed to determine who underwent preoperative MRI. Breast tissue density was determined with mammography according to ACR BI-RADS. Patients were compared according to tumor size, grade, stage, and treatment. Survival analysis was performed using Kaplan-Meier estimates. Results In total, 261 patients with mean follow-up of 85 months (25–133) were included: 156 DB and 105 NDB. Disease-free survival outcomes were better in the DB group in patients with MRI than in those without MRI: patients with MRI had significantly fewer local recurrences (P < 0.016) and metachronous contralateral breast cancers (P < 0.001), but this was not the case in the NDB group. Mastectomies were higher in the DB group with preoperative MRI than in those without MRI (P < 0.01), as it was in the NDB group (P > 0.05). Conclusions Preoperative breast MRI was associated with reduced local recurrence and metachronous contralateral cancers in the DB group, but not in the NDB group; however, the DB patients with MRI had higher mastectomy rates.

Phase I study of sequential sapacitabine and seliciclib in patients with advanced solid tumors.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 3053-3053
Author(s):  
Geoffrey Shapiro ◽  
Eunice Lee Kwak ◽  
James M. Cleary ◽  
Sara Tolaney ◽  
Leena Gandhi ◽  
...  
Keyword(s):  
Dna Damage ◽  
Phase I ◽  
Mutation Carrier ◽  
Phase I Study ◽  
Brca Mutation ◽  
Fold Increase ◽  
Brca Mutation Carrier ◽  
Dna Breaks ◽  
Dsb Repair ◽  
Skin Biopsies

3053 Background: Sapacitabine is an orally administered nucleoside analogue; the active metabolite CNDAC generates ss DNA breaks that are converted to ds DNA breaks (DSB) during subsequent replication, resulting in cell death if unrepaired. CNDAC-induced DSB repair is dependent on homologous recombination (HR). Seliciclib is a potent orally bioavailable inhibitor of CDK2, 7 and 9, and sensitizes cells to CNDAC by decreasing DSB repair via compromise of HR protein activation and transcriptional inhibition of HR components. This phase I study evaluates sequential sapacitabine and seliciclib. Methods: Dose escalation was conducted in patients with incurable solid tumors and adequate organ function with sapacitabine b.i.d. x 7 consecutive days (d1-7), seliciclib b.i.d. x 3 consecutive days (d8-10) followed by 11 days of rest. At least 3 patients were evaluated per dose level. MTD was the highest dose level at which less than one-third of at least 6 patients experienced cycle 1 DLT. Skin biopsies were obtained to assess DNA damage following sapacitabine (d8 vs pre-treatment) and further augmentation of DNA damage after seliciclib (d11 vs d8). Results: 27 patients were treated. The MTD and RP2D is sapacitabine 50 mg b.i.d./seliciclib 1200 mg b.i.d. DLTs were reversible transaminase elevations and neutropenia. The most frequent adverse events (all cycles, regardless of causality) included anorexia, fatigue, abdominal pain, dizziness, nausea, anemia, neutropenia, creatinine elevation, hyperglycemia, hyperbilirubinemia, hypophosphatemia, hypokalemia and hypomagnesemia, the majority mild to moderate in intensity. Skin biopsies showed a 2.3-fold increase in H2AX staining post-sapacitabine (n=16; p=0.007) and a further 0.58-fold increase post-seliciclib (n=12; p=0.069). Two confirmed PRs occurred in patients with pancreatic and breast cancer, both BRCA mutation carriers. SD as best response >/= 12 weeks was observed in 6 additional patients, including one BRCA mutation carrier with ovarian cancer (ongoing at 24 weeks). Conclusions: Sequential sapacitabine and seliciclib is safe with preliminary antitumor activity. BRCA mutation carrier status may be a potential biomarker for response across multiple tumor types.

Sign in / Sign up

Export Citation Format

Share Document